Consolidated results for the second quarter of the fiscal year ending March 2027: net sales 10,437 million yen, operating loss 1,036 million yen, interim net loss attributable to owners of parent 1,749 million yen. Cost of sales ratio rose to 44.4%. Both Japan and U.S. business segments recorded losses. Total assets at the end of the interim period were 33,528 million yen and net assets were 23,070 million yen. Full-year forecasts for 2027 were revised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7600","jir_company_name":"Japan Medical Dynamic Marketing, INC.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7600-20261104-01.pdf","jir_short_summary":"Consolidated results for the second quarter of the fiscal year ending March 2027: net sales 10,437 million yen, operating loss 1,036 million yen, interim net loss attributable to owners of parent 1,749 million yen. Cost of sales ratio rose to 44.4%. Both Japan and U.S. business segments recorded losses. Total assets at the end of the interim period were 33,528 million yen and net assets were 23,070 million yen. Full-year forecasts for 2027 were revised.","jir_summary":"### Overview of Results\nFor the period, consolidated net sales amounted to 10,437 million yen, a 10.1% decrease year-over-year. The decline reflects reduced demand at the U.S. subsidiary, foreign exchange impacts, and deteriorating sales across product lines, resulting in an operating loss. Both Japan and U.S. segments posted losses. The cost of sales ratio rose to 44.4%, mainly due to increased burden of fixed manufacturing costs and higher import costs from yen depreciation. The interim net loss expanded to 1,749 million yen. The financial position declined to total assets of 33,528 million yen and net assets of 23,070 million yen at the interim period end. Supplementary financial materials are available and an earnings presentation will be held.\n\n### Outlook and Matters Going Forward\nThe full-year earnings forecast for the fiscal year ending March 2027 has been revised and disclosed. Subsequent events in the interim period include rationalization and personnel reductions at the U.S. subsidiary, and retirement-related expenses are expected to be recorded in fiscal 2027. There is a possibility of further disclosures regarding shareholder return policy and additional revisions to earnings guidance. For both Japan and U.S. segments, restoring profitability remains a challenge; controlling selling, general and administrative expenses and improving cost structure are key.","jir_financial_highlights":"Net Sales: 10,437 million yen (Year-over-Year -10.1%)\nOperating Loss: -1,036 million yen (Prior-year same period recorded a 208 million yen profit)\nOrdinary Loss: -1,161 million yen (Prior-year same period recorded a 130 million yen profit)\nInterim Net Loss Attributable to Owners of Parent: -1,749 million yen (Prior-year same period recorded a 69 million yen profit)\nTotal Assets: 33,528 million yen (Year-end comparison -2,150 million yen)\nNet Assets: 23,070 million yen (Year-end comparison -2,356 million yen)","jir_category":"","jir_hashtags":"#JapanMedicalDynamicMarketing, #Earnings, #InterimResults, #SegmentSales","jir_key_figures":"Net Sales: 10,437 million yen (Year-over-Year -10.1%)\nOperating Loss: -1,036 million yen\nInterim Net Loss Attributable to Owners of Parent: -1,749 million yen\nTotal Assets: 33,528 million yen\nNet Assets: 23,070 million yen","jir_meta_title":"Japan Medical Dynamic Marketing, INC. Second Quarter Financial Summary for FY March 2027 | Net Sales 10,437 million yen, Enlarged Net Loss","jir_meta_description":"Financial summary for Japan Medical Dynamic Marketing, INC. for the second quarter of FY March 2027. Net sales were 10,437 million yen, operating loss 1,036 million yen, and net loss 1,749 million yen. Details on segment losses, drivers of rising cost ratios, and changes in financial position are provided. A revision to the full-year forecast has been disclosed.","jir_og_title":"Japan Medical Dynamic Marketing, INC. Second Quarter Financial Summary for FY March 2027","jir_og_description":"Second quarter results: net sales 10,437 million yen, operating loss 1,036 million yen, net loss 1,749 million yen. Main causes include reduced demand by product and rising costs. Full-year forecasts have been revised. See the financial summary for details.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[10437,10437,10437]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/4\\\",\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-1, -1, -1036]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"U.S.\\\"],\\\"datasets\\\":[{\\\"data\\\":[5475,6721]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Cost of Sales Ratio and SG&A Ratio Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026 Interim\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cost of Sales Ratio\\\",\\\"data\\\":[44.4]} , {\\\"label\\\":\\\"SG&A to Net Sales Ratio\\\",\\\"data\\\":[65.5]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Full-Year Forecast and Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Full-Year Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast Net Sales\\\",\\\"data\\\":[\u2014]}]},\\\"options\\\":{}}\"}]","ir_related_company":58545,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141198","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n